Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA.

It is an autoimmune disorder when body’s own immune cell starts attacking healthy cells. This results in inflammation. It is also known as “systemic onset juvenile rheumatoid arthritis”It makes the joints inflamed and stiff for more than six weeks.

DelveInsight report on Systemic Juvenile Idiopathic Arthritis provides comparative study of drugs under development. The report provides assessment of Tofacitinib pipeline drug by Pfizer Phase III. In addition to this, the report imparts information on several other drugs as well.

Key Highlights of Report:

• Comprehensive insights about pipeline drugs across this indication
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages
• Therapeutics assessment by monotherapy and combination products and molecule type drug information
• Companies involved in therapeutic development of the products
• Discontinued and dormant products

DelveInsight is offering the Report at a price of US 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

.